Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice

Pharmacology

Volumn 57, Issue 5, 1998, Pages 229-232

  Sharma, Shyam Sunder ^a   Bhargava, Hemendra N ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antinociception; Ibogaine; Morphine; Noribogaine; Tolerance

Indexed keywords

ALKALOID; IBOGAINE; MORPHINE; NORIBOGAINE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; MALE; MORPHINE TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANALGESICS, OPIOID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; DRUG SYNERGISM; DRUG TOLERANCE; HALLUCINOGENS; IBOGAINE; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MORPHINE; PAIN;

EID: 0031668951     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028246     Document Type: Article

References (12)

1. Bhargava HN: Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome and self-administrative behavior. Pharmacol Rev 1994;46: 293-324.
2. Lotsof H: Rapid method for interrupting the narcotic addiction syndromes. US Patent 1985;4.
3. Glick SD, Rossman K, Steindorf S, Maisonneuve IM, Carlson JM: Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur J Pharmacol 1991;195: 341-345.
4. Bhargava HN, Cao YJ, Zhao GM: Effects of ibogaine and noribogaine on the antinociceptive action of μ-, δ- and κ-opioid receptor agonists in mice. Brain Res 1997;752:234-238.
5. Francis B, Gout R, Gros J, Zajac JM: Effects of ibogaine on naloxone precipitated withdrawal in morphine dependent mice. Fundam Clin Pharmacol 1992;6:327-332.
6. Schneider JA, McArthurM: Polentiation action of ibogaine (Bogadin™) on morphine analgesia. Experientia 1956;12:323-324.
7. Bhargava HN, Cao YJ: Effects of noribogaine on the development of tolerance to antinociceptive action of morphine in mice. Brain Res 1997;771:343-346.
8. Cao YJ, Bhargava HN: Effects of ibogaine on the development of tolerance to antinociceptive action of μ-, δ- and κ-opioid receptor agonists in mice. Brain Res 1997;752:250-254.
9. Codd EE: High affinity ibogaine binding to a mu opioid agonists site. Life Sci 1995;57:PL315-320.
10. Deecher DC, Teitler M, Soderlund DM, Boenmann WG, Kuekne ME, Click SD: Mechanism of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res 1992;571:242-247.
11. Pearl SM, Davis KH, Teitler M, Glick SD: Radioligand binding study of noribogaine, a likely metabolite of ibogaine. Brain Res 1995; 675:342-344.
12. Popik P, Layer RT, Fossom LH, Benveniste M, Gieter-Douglass B, Witkin JM, Skolnick P: NMDA antagonist properties of the putative antiaddictive drug, ibogaine. J Pharmacol Exp Ther 1995;275:753-760.